#Obesity medicine
Chronic weight management as a clinical specialty.
DNA-based GLP-1 delivery via MYO Technology
A single injection of plasmid DNA encoding GLP-1 produced sustained weight loss for over a year in obese mice. What the data shows.
GLP-1 drugs and lipedema: early evidence
A 2026 Dermatologic Surgery review found only two studies of GLP-1 receptor agonists in lipedema. The rationale is real, but the clinical evidence is thin.
What Penn Medicine's 'food noise' case study actually showed
Casey Halpern's Nature Medicine case study recorded nucleus-accumbens activity in a single patient on tirzepatide. Activity was suppressed early, then returned at 5 months alongside renewed cravings.
Tirzepatide in the UK: how NICE TA924 and TA1026 shape access
Two NICE technology appraisals decide who gets Mounjaro on the NHS and under what criteria. TA924 covers type-2 diabetes; TA1026 covers obesity. They do not overlap.
TRIUMPH-1: retatrutide hits 28.3% weight loss at 80 weeks
Eli Lilly's first general-obesity Phase 3 readout for retatrutide: 28.3% mean body-weight reduction at 80 weeks on 12 mg weekly. Larger than any SURMOUNT-5 figure to date.